Profile data is unavailable for this security.
About the company
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
- Revenue in USD (TTM)100.33bn
- Net income in USD31.37bn
- Incorporated1942
- Employees83.00k
- LocationPfizer Inc66 HUDSON BOULEVARD EASTNEW YORK 10001-2192United StatesUSA
- Phone+1 (212) 733-2323
- Fax+1 (302) 655-5049
- Websitehttps://www.pfizer.com/
Mergers & acquisitions
Acquired company | PFE:NYQ since announced | Transaction value |
---|---|---|
Seagen Inc | 2.51% | 43.84bn |
Global Blood Therapeutics Inc | -18.04% | 5.07bn |
Biohaven Pharmaceutical Holding Co Ltd | -16.98% | 12.60bn |
ReViral Ltd | -23.62% | 525.00m |